NasdaqGS:INSMBiotechs
A Look At Insmed (INSM) Valuation As Brensocatib Gains Early Traction And New Equity Awards Signal Growth
Insmed (INSM) is back in focus after reporting strong early physician conviction and broad prescribing intent for its newly launched drug brensocatib, along with fresh equity awards for more than 100 newly hired employees.
See our latest analysis for Insmed.
Despite strong interest in brensocatib and recent equity awards tied to new hiring, Insmed’s share price has come under pressure, with a 1-day share price return of down 10.20% and a year to date share price return of down 46.80%. At the...